pharmaceuticals AM market analysis — 2026-09-30
Pharmaceutical sponsors continue to face substantial attrition across clinical development, which keeps trial design and execution central to how value is created in the sector. Historical success-rate analysis from BIO shows that programme risk is concentrated across multiple development stages, reinforcing why companies are investing in analytics that span discovery, clinical trials, manufacturing and post-market review, as outlined by Revvity Signals.
Separately, US trade and domestic-manufacturing policy is pushing companies to reassess supply-chain sourcing and production location, according to Chemistry Today. The direction of that pressure favours greater localisation and regulatory preparedness, though the pace and scope of implementation remain unsettled.
FDA approval activity, tracked through the agency’s 2026 novel-drug approvals resource, offers a live indicator of pipeline progress and regulatory momentum. Sponsors with active pivotal trials and firms exposed to supply-chain policy changes are the two groups most likely to see their outlook shift in the near term.
Worth Tracking
- Pivotal trial readoutsClinical outcomes remain the primary swing factor for individual sponsors given high development-stage attrition.
- Supply-chain localisation policyTrade and manufacturing-policy shifts could affect sourcing costs and launch timelines.
- FDA novel-drug approval activityApproval and labelling decisions can shift competitive positioning within therapeutic areas.
This analysis was generated automatically and is for information only — not financial advice.